Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316821310> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2316821310 endingPage "A72" @default.
- W2316821310 startingPage "A72" @default.
- W2316821310 abstract "<h3>Introduction</h3> Tyrosine kinase inhibition has shown inconsistent success in the treatment of idiopathic pulmonary fibrosis (IPF). While a study of imatinib showed no impact on survival or lung function in a placebo-controlled study, two recently announced placebo-controlled phase 3 trials of nintedanib demonstrated statistically significant impact on forced vital capacity. Comparing the kinase target profiles could inform future target selection for drugs in IPF. <h3>Methods</h3> <i>In vitro</i> kinase selectivity data of nintedanib and imatinib were collected using the kinomescan platform (DiscoveRx Inc). Binding data (% binding) for 451 human kinases (~80% of the human kinome) were initially collected at a single concentration (10 uM). For kinases that displayed significant binding, potencies (K<sub>D</sub>) were measured in dose-response format. <h3>Results</h3> At a common concentration of 100 nM, imatinib and nintedanib bound to 12 and 50 kinases, respectively. Maximal drug concentrations (C<sub>max</sub>) observed in patients were used to project therapeutically relevant kinase inhibition for both drugs. Using these criteria, nintedanib binds 44 kinases at drug levels seen in patients (K<sub>D</sub> < C<sub>max </sub>of 64 nM). Imatinib binds 34 kinases at drug levels seen in patients (K<sub>D</sub> < C<sub>max </sub>of 7500 nM). 14 kinases were bound by both compounds, including PDGFRA, PDGFRB and VEGFR2. <h3>Conclusions</h3> Our results suggest that nintedanib and imatinib have partially overlapping inhibition profiles; the kinases that are targeted by both agents are unlikely to be responsible for efficacy differences. Further work is required to identify which of the remaining kinase target (s) are responsible for efficacy in IPF and could therefore represent targets for follow-up compounds." @default.
- W2316821310 created "2016-06-24" @default.
- W2316821310 creator A5034168880 @default.
- W2316821310 creator A5043893319 @default.
- W2316821310 creator A5049095050 @default.
- W2316821310 creator A5072647330 @default.
- W2316821310 creator A5086313400 @default.
- W2316821310 date "2014-11-10" @default.
- W2316821310 modified "2023-09-25" @default.
- W2316821310 title "S134 Kinase Selectivity Profiles Of Nintedanib And Imatinib" @default.
- W2316821310 doi "https://doi.org/10.1136/thoraxjnl-2014-206260.140" @default.
- W2316821310 hasPublicationYear "2014" @default.
- W2316821310 type Work @default.
- W2316821310 sameAs 2316821310 @default.
- W2316821310 citedByCount "2" @default.
- W2316821310 countsByYear W23168213102017 @default.
- W2316821310 countsByYear W23168213102022 @default.
- W2316821310 crossrefType "journal-article" @default.
- W2316821310 hasAuthorship W2316821310A5034168880 @default.
- W2316821310 hasAuthorship W2316821310A5043893319 @default.
- W2316821310 hasAuthorship W2316821310A5049095050 @default.
- W2316821310 hasAuthorship W2316821310A5072647330 @default.
- W2316821310 hasAuthorship W2316821310A5086313400 @default.
- W2316821310 hasBestOaLocation W23168213101 @default.
- W2316821310 hasConcept C121608353 @default.
- W2316821310 hasConcept C126322002 @default.
- W2316821310 hasConcept C170493617 @default.
- W2316821310 hasConcept C184235292 @default.
- W2316821310 hasConcept C185592680 @default.
- W2316821310 hasConcept C2777583451 @default.
- W2316821310 hasConcept C2777714996 @default.
- W2316821310 hasConcept C2778341716 @default.
- W2316821310 hasConcept C2778729363 @default.
- W2316821310 hasConcept C2778820342 @default.
- W2316821310 hasConcept C2780171596 @default.
- W2316821310 hasConcept C42362537 @default.
- W2316821310 hasConcept C502942594 @default.
- W2316821310 hasConcept C54174078 @default.
- W2316821310 hasConcept C55493867 @default.
- W2316821310 hasConcept C71924100 @default.
- W2316821310 hasConcept C98274493 @default.
- W2316821310 hasConceptScore W2316821310C121608353 @default.
- W2316821310 hasConceptScore W2316821310C126322002 @default.
- W2316821310 hasConceptScore W2316821310C170493617 @default.
- W2316821310 hasConceptScore W2316821310C184235292 @default.
- W2316821310 hasConceptScore W2316821310C185592680 @default.
- W2316821310 hasConceptScore W2316821310C2777583451 @default.
- W2316821310 hasConceptScore W2316821310C2777714996 @default.
- W2316821310 hasConceptScore W2316821310C2778341716 @default.
- W2316821310 hasConceptScore W2316821310C2778729363 @default.
- W2316821310 hasConceptScore W2316821310C2778820342 @default.
- W2316821310 hasConceptScore W2316821310C2780171596 @default.
- W2316821310 hasConceptScore W2316821310C42362537 @default.
- W2316821310 hasConceptScore W2316821310C502942594 @default.
- W2316821310 hasConceptScore W2316821310C54174078 @default.
- W2316821310 hasConceptScore W2316821310C55493867 @default.
- W2316821310 hasConceptScore W2316821310C71924100 @default.
- W2316821310 hasConceptScore W2316821310C98274493 @default.
- W2316821310 hasIssue "Suppl 2" @default.
- W2316821310 hasLocation W23168213101 @default.
- W2316821310 hasLocation W23168213102 @default.
- W2316821310 hasOpenAccess W2316821310 @default.
- W2316821310 hasPrimaryLocation W23168213101 @default.
- W2316821310 hasRelatedWork W1969352420 @default.
- W2316821310 hasRelatedWork W1995217826 @default.
- W2316821310 hasRelatedWork W2008702706 @default.
- W2316821310 hasRelatedWork W2015608796 @default.
- W2316821310 hasRelatedWork W2100041900 @default.
- W2316821310 hasRelatedWork W2255659411 @default.
- W2316821310 hasRelatedWork W2316821310 @default.
- W2316821310 hasRelatedWork W2751395222 @default.
- W2316821310 hasRelatedWork W2775730895 @default.
- W2316821310 hasRelatedWork W2902072959 @default.
- W2316821310 hasVolume "69" @default.
- W2316821310 isParatext "false" @default.
- W2316821310 isRetracted "false" @default.
- W2316821310 magId "2316821310" @default.
- W2316821310 workType "article" @default.